Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions
Nan Chiang, … , Xavier de la Rosa, Charles N. Serhan
Nan Chiang, … , Xavier de la Rosa, Charles N. Serhan
Published October 28, 2019
Citation Information: J Clin Invest. 2019;129(12):5294-5311. https://doi.org/10.1172/JCI129448.
View: Text | PDF | Corrigendum
Research Article Inflammation Article has an altmetric score of 9

Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions

  • Text
  • PDF
Abstract

Resolution of acute inflammation is an active process orchestrated by endogenous mediators and mechanisms pivotal in host defense and homeostasis. The macrophage mediator in resolving inflammation, maresin 1 (MaR1), is a potent immunoresolvent, stimulating resolution of acute inflammation and organ protection. Using an unbiased screening of greater than 200 GPCRs, we identified MaR1 as a stereoselective activator for human leucine-rich repeat containing G protein–coupled receptor 6 (LGR6), expressed in phagocytes. MaR1 specificity for recombinant human LGR6 activation was established using reporter cells expressing LGR6 and functional impedance sensing. MaR1-specific binding to LGR6 was confirmed using 3H-labeled MaR1. With human and mouse phagocytes, MaR1 (0.01–10 nM) enhanced phagocytosis, efferocytosis, and phosphorylation of a panel of proteins including the ERK and cAMP response element-binding protein. These MaR1 actions were significantly amplified with LGR6 overexpression and diminished by gene silencing in phagocytes. Thus, we provide evidence for MaR1 as an endogenous activator of human LGR6 and a novel role of LGR6 in stimulating MaR1’s key proresolving functions of phagocytes.

Authors

Nan Chiang, Stephania Libreros, Paul C. Norris, Xavier de la Rosa, Charles N. Serhan

×

Figure 5

MaR1-LGR6–dependent binding, signal, and phagocytosis: knockdown of human LGR6.

Options: View larger image (or click on image) Download as PowerPoint
MaR1-LGR6–dependent binding, signal, and phagocytosis: knockdown of huma...
(A and B) LGR6 knockdown in THP-1 cells. (A) Gating strategy: Cells were gated on FSC-SSC dot plots (left), GFP+ populations were selected on the histograms (middle), then LGR6 expression was determined within the GFP+ population (right). (B) LGR6 expression (MFI) in GFP+ THP-1 cells. Results are mean ± SEM (n = 4). ****P < 0.001 versus control shRNA (Ren 713) and mock vector. (C) [3H]-MaR1 binding. THP-1 cells were incubated with 2-nM [3H]-MaR1-ME in the presence or absence of unlabeled 1-μM MaR1-ME for 60 minutes at 4°C. Results are specific binding (CPM), calculated as total CPM ([3H]-MaR1 plus vehicle) – nonspecific CPM ([3H]-MaR1 plus unlabeled MaR1-ME). Results are mean ± SEM (n = 3). *P < 0.05, versus shRNA LGR6. Two-tailed paired Student’s t test. (D) cAMP. THP-1 cells were incubated with MaR1 (1–100 nM) for 15 minutes and cAMP levels determined. Results are mean ± SEM (n = 3). **P < 0.01, versus shRNA LGR6; ##P < 0.01, versus 1 nM (mock vector). (E–H) Phagocytosis. THP-1 cells were incubated with 10-nM MaR1 or vehicle (0.01% ethanol) for 15 minutes prior to addition of BacLight Red-labeled (PE-Texas Red) E. coli (1:50 THP-1:E.coli) for 45 minutes at 37°C. Flow cytometry was carried out. (E) Representative histograms for GFP (top panels), GFP+ BacLight Red E. coli+ (middle panels) and GFP- BacLight Red E. coli+ (bottom panels). (F) Quantification of BacLight Red E. coli (MFI) in GFP+ cells (top) and GFP- cells (bottom). Results are mean ± SEM (n = 3). *P < 0.05; **P < 0.01, MaR1 versus vehicle. (G) Structures of MaR1 and 12E-MaR1 (left) and representative histograms (right) of BacLight Red E. coli in GFP+ cells. (H) Percent increase of phagocytosis. ****P < 0.0001, versus MaR1-treated mock vector transfected cells. (B and H) One-way ANOVA or (D and F) 2-way ANOVA with Tukey’s multiple comparisons test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 12 X users
138 readers on Mendeley
See more details